955823-06-0

Basic information

• Product Name: 4-methyl-N-(5-nitrobenzo[d]thiazol-2-yl)benzamide
• Synonyms: 4-methyl-N-(5-nitrobenzo[d]thiazol-2-yl)benzamide
• CAS NO: 955823-06-0
• Molecular Weight: 313.337
• Mol File: 955823-06-0.mol

Chemical Properties

• CAS DataBase Reference: 4-methyl-N-(5-nitrobenzo[d]thiazol-2-yl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-methyl-N-(5-nitrobenzo[d]thiazol-2-yl)benzamide(955823-06-0)
• EPA Substance Registry System: 4-methyl-N-(5-nitrobenzo[d]thiazol-2-yl)benzamide(955823-06-0)

Safety Data

• Hazardous Substances Data: 955823-06-0(Hazardous Substances Data)

Upstream product

• 333415-02-4 N-[(2-fluoro-5-nitrophenyl)carbamothioyl]-4-methyl-benzamide 
• 874-60-2 4-methyl-benzoyl chloride 

Downstream Products

• 1428620-37-4 methyl 2-{5-amino-2-[(4-methylbenzoyl)imino]benzo[d]thiazol-3(2H)-yl}butanoate 
• 1428620-38-5 methyl 2-{5-acetamido-2-[(4-methylbenzoyl)imino]benzo[d]thiazol-3(2H)-yl}butanoate 
• 1428620-36-3 methyl 2-{5-nitro-2-[(4-methylbenzoyl)imino]benzo[d]thiazol-3(2H)-yl}butanoate 

Relevant articles and documents

PHENYLIMIDE-CONTAINING BENZOTHIAZOLE DERIVATIVE OF ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

Provided is a phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt can selectively inhibit the protein-protein interaction between KRS and a laminin receptor (LR), thereby inhibiting migration of cancer cells. Therefore, the phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt may be usefully applied for preventing or treating the diseases associated with cancer cell metastasis.

PHENYLIMIDE-CONTAINING BENZOTHIAZOLE DERIVATIVE OR ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention provides a phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt can selectively inhibit the protein-protein interaction between KRS and a laminin receptor (LR), thereby inhibiting migration of cancer cells. Therefore, the phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt may be usefully applied for preventing or treating the diseases associated with cancer cell metastasis.